Hemagen Diagnostics, Inc. (HMGN)

Market Cap	312.33K
Revenue (ttm)	4.04M
Net Income (ttm)	-907.32K
Shares Out	15.50M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	22,974
Open	0.0202
Previous Close	n/a
Day's Range	0.0202 - 0.0202
52-Week Range	0.0000 - 0.0402
Beta	1,082.76
RSI	57.03
Earnings Date	n/a

About Hemagen Diagnostics

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1985
• Employees: 15
• Stock Exchange: OTCMKTS
• Ticker Symbol: HMGN

Financial Performance

In 2012, Hemagen Diagnostics's revenue was $4.04 million, a decrease of -21.38% compared to the previous year's $5.14 million. Losses were -$907,315, 3.05% more than in 2011.